Sponsor Dossier
Cipla
Sponsor Dossier for Cipla. ARTG portfolio, PBS-listed brands, PBAC activity, AusPAR record — compiled by arcimedes.
- Brand: ACIVIR
- Brand: ADALICIP
- Brand: AMBRICIP
- Brand: AMCAL
- Brand: Anterone
- Brand: APIXABAN CIPLA
- Brand: APIXAIR
- Brand: APOHEALTH
- Device (sponsor): Medicine chamber spacer
- Device (sponsor): Non-sterile scar management dressing, reusable
- Device (sponsor): Irrigation fluid, nasal
- Device (sponsor): Dressing, occlusive, silicone
About
Cipla is an Australian Private Company with ABN 46 132 155 063, registered in Victoria. The entity is active and registered for GST from 2008.
Portfolio
Cipla has 139 brands on the ARTG, of which 41 are indexable. The portfolio includes 34 brands with Product Information on file, 2 brands with PBS-listed items, 6 brands with PBAC outcomes on record, and 6 brands with AusPARs on record.
Therapeutic focus
— Oncology: 40 brands — Respiratory: 21 brands — Neurology: 17 brands — Cardiology: 14 brands — Infectious Disease: 14 brands — Pain Management: 6 brands — Pain & Anaesthesia: 6 brands — Immunology: 4 brands — Endocrinology: 4 brands — Gastroenterology: 3 brands — Urology: 3 brands — Haematology: 2 brands — Rare Disease: 2 brands — Ophthalmology: 1 brand — Renal: 1 brand — Dermatology: 1 brand
PBS footprint
Two brands in Cipla's portfolio are PBS-listed, with the latest schedule date touched on 1 May 2026.
Regulatory activity
Cipla's latest PBAC outcome was on 1 November 2023, with 6 brands holding PBAC outcomes on record. The latest AusPAR was issued on 20 January 2025, with 6 brands holding AusPARs on record.